Health Press Release – Newsletter for December 1, 2010

IDEV Technologies Announces First U.S. Procedure With SUPERA VERITAS(TM) Transhepatic Biliary System

Commercial Launch of Stent Delivery System Planned for Early 2011
WEBSTER, Texas, November 30, 2010 – IDEV Technologies, Incorporated (IDEV), an innovative leader in the
development and commercialization of minimally invasive medical technologies,
today announced the first procedure in the United States utilizing the SUPERA
VERITAS(TM) Transhepatic Biliary System, which was recently cleared to market
by the U.S. Food …. Source article on Gaea Times at  : IDEV Technologies Announces First U.S. Procedure With SUPERA VERITAS(TM) Transhepatic Biliary System.

UK’s Indoor Air is Under Attack by Parliament

SURREY, England, November 30, 2010 – The Parliamentary Office of Science and Technology (POST) reports that
poor indoor air can cause ill health and disease, and that "no single
government department has ownership of this issue." Simultaneously, Asthma UK
unveiled research that named indoor triggers that cause asthma in the first
place.

These two significant …. Source  : Gaea News Network.

Life Healthcare Upbeat After Robust Maiden Results

JOHANNESBURG, November 30, 2010 – Life Healthcare Group Holdings Limited ("Life Healthcare" or the
"Group"), a leading provider of private healthcare services in southern
Africa, today released its maiden set of annual financial results for the
year ended 30 September 2010 since listing on the JSE on 10 June.

Highlights of the results include:

… Original source on Gaea Times at : Life Healthcare Upbeat After Robust Maiden Results.

Medivation and Astellas Complete Enrollment in Phase 3 AFFIRM trial of MDV3100 in Advanced Prostate Cancer

SAN FRANCISCO and TOKYO, November 30, 2010 – Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. today announced
that patient enrollment was completed on November 15, 2010 in the Phase 3
AFFIRM study of the investigational drug MDV3100, a novel, triple-acting oral
androgen receptor antagonist, in patients with advanced prostate cancer who
have previously been treated with chemotherapy.

… Read more »»».

HCL Technologies Enters Into Multi Year end-to-end IT Infrastructure Management Engagement With Purdue Pharma L.P.

NOIDA, India, November 30, 2010 – HCL Technologies Ltd. (HCL), a leading global IT services
provider, today announced that it has signed a multi year end-to-end IT
Infrastructure Management engagement with pharmaceutical company Purdue
Pharma L.P. The scope of this engagement covers management of two data
centers and all remote locations of the client in the U.S.

[..] Read the original article: here.

Gen-Probe Launches PANTHER(TM) System, Fully Automated and Integrated Molecular Testing Instrument, in Europe

System Offers Revolutionary Productivity and Flexibility for Laboratories
SAN DIEGO, November 30, 2010 – Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company's
PANTHER(TM) system, a fully automated and integrated molecular testing system
designed with the flexibility to handle a wide range of testing needs, has
been CE-marked and is available for sale in Europe.

…. Original article on Gaea Times at  : Gen-Probe Launches PANTHER(TM) System, Fully Automated and Integrated Molecular Testing Instrument, in Europe.

Bring in Group B Strep Testing for all Women to Save Money and Lives, Urges Group B Strep Support

HAYWARDS HEATH, England, December 1, 2010 – Group B Strep Support (GBSS), the charity for the UK's biggest cause of
life-threatening infection newborn babies, is urging the Government to make
sensitive testing for group B Streptococcus (GBS) available for all pregnant
women, as recent research shows this would save money as well as tiny babies'
lives.

… Original source on Gaea Times at : Bring in Group B Strep Testing for all Women to Save Money and Lives, Urges Group B Strep Support.